Thomas C. Chen
Known title: CEOCIK: 0001998682
Thomas C. Chen's purchase track record
Thomas C. Chen has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/11/2026 | NTHI | $40K | pending | pending | — |
| 8/14/2026 | NTHI | $210K | pending | pending | — |
| 5/21/2025 | NTHI | $40K | -25.7% | -6.3% | +13.7% |
| 5/12/2025 | NTHI | $3K | -16.5% | +65.7% | +16.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| NTHI | ▲ Buy | Open Market | 5,242 | $20K | 9/14/2026 | View on chart |
| NTHI | ▲ Buy | Open Market | 5,556 | $20K | 9/11/2026 | View on chart |
| NTHI | ▲ Buy | Open Market | 12,757 | $70K | 8/18/2026 | View on chart |
| NTHI | ▲ Buy | Open Market | 2,472 | $10K | 8/17/2026 | View on chart |
| NTHI | ▲ Buy | Open Market | 33,787 | $130K | 8/14/2026 | View on chart |
| NTHI | ▲ Buy | Open Market | 2,709 | $20K | 5/22/2025 | View on chart |
| NTHI | ▲ Buy | Open Market | 2,759 | $20K | 5/21/2025 | View on chart |
| NTHI | ▲ Buy | Open Market | 400 | $3K | 5/12/2025 | View on chart |
| NTHI | ▼ Sell | Other | 4,076 | $0 | 3/26/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
NeOnc Sets FDA Meeting for NEO212; Roth Starts Coverage
NeOnc Technologies has scheduled an in-person FDA End-of-Phase 1 meeting for November 17 regarding its NEO212 candidate. This regulatory milestone provides a clear next step for the company's development timeline. Additionally, Roth Capital initiated coverage with a price target of $20, which is at the top of the current analyst range.
NeOnc Sets FDA Meeting for NEO212; Roth Starts Coverage. NeOnc Technologies has scheduled an in-person FDA End-of-Phase 1 meeting for November 17 regarding its NEO212 candidate. This regulatory milestone provides a clear next step for the company's development timeline. Additionally, Roth Capital initiated coverage with a price target of $20, which is at the top of the current analyst range.